CHEK2 and breast carcinoma: Against our expectations based on the results from previous studies, CHEK2 c.1100delC associated ER-positive breast cancer patients had similar recurrent disease-free survival, distant disease-free survival, breast cancer-specific survival and overall survival as compared to non-carriers.